Foundation Medicine Inc. (FMI)

71.95
0.80 1.10
NASDAQ : Health Technology
Prev Close 72.75
Open 72.40
Day Low/High 71.70 / 73.22
52 Wk Low/High 31.70 / 87.10
Volume 72.53K
Avg Volume 314.40K
Exchange NASDAQ
Shares Outstanding 36.88M
Market Cap 2.61B
EPS -4.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Foundation Medicine Advances Patient Access To Precision Medicine; Pursues Regulatory Approval For FoundationOne CDx™ In Japan

Foundation Medicine Advances Patient Access To Precision Medicine; Pursues Regulatory Approval For FoundationOne CDx™ In Japan

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that Chugai Pharmaceutical Co.

Foundation Medicine And Guardant Health Agree To Resolve False Advertising Lawsuit

Foundation Medicine And Guardant Health Agree To Resolve False Advertising Lawsuit

Foundation Medicine, Inc. (NASDAQ:FMI) and Guardant Health, Inc.

Foundation Medicine To Present At Cowen And Company's 38th Annual Healthcare Conference

Foundation Medicine To Present At Cowen And Company's 38th Annual Healthcare Conference

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at Cowen & Company's 38 th Annual Healthcare Conference on Wednesday, March 14, 2018, at 10:40 a.

Foundation Medicine Announces 2017 Fourth Quarter And Year-End Results, Recent Highlights And 2018 Outlook

Foundation Medicine Announces 2017 Fourth Quarter And Year-End Results, Recent Highlights And 2018 Outlook

Foundation Medicine (NASDAQ:FMI) today reported financial and operational results for the fourth quarter and year ended December 31, 2017.

Foundation Medicine Announces Timing For Fourth Quarter And Year-End 2017 Financial Results And Conference Call

Foundation Medicine Announces Timing For Fourth Quarter And Year-End 2017 Financial Results And Conference Call

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's fourth quarter and year ended December 31, 2017 will be released on Wednesday, March 7, 2018.

Foundation Medicine And European Organisation For Research And Treatment Of Cancer (EORTC) Announce Collaboration To Advance Precision Medicine Using Comprehensive Genomic Profiling To Facilitate Clinical Trial Enrollment

Foundation Medicine And European Organisation For Research And Treatment Of Cancer (EORTC) Announce Collaboration To Advance Precision Medicine Using Comprehensive Genomic Profiling To Facilitate Clinical Trial Enrollment

Foundation Medicine, Inc. (NASDAQ:FMI) and the European Organisation for Research and Treatment of Cancer (EORTC) announced today a collaboration in which Foundation Medicine's comprehensive genomic profiling (CGP)...

Foundation Medicine And Pfizer Announce Broad Partnership To Develop Companion Diagnostics For Pfizer's Oncology Portfolio

Foundation Medicine And Pfizer Announce Broad Partnership To Develop Companion Diagnostics For Pfizer's Oncology Portfolio

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company has entered into a broad partnership with Pfizer Inc.

Foundation Medicine Reports Preliminary 2017 Results

Foundation Medicine Reports Preliminary 2017 Results

Foundation Medicine (NASDAQ:FMI) today announced preliminary unaudited total revenue of approximately $48.

Foundation Medicine To Present At The 36th Annual J.P. Morgan Healthcare Conference

Foundation Medicine To Present At The 36th Annual J.P. Morgan Healthcare Conference

Foundation Medicine today announced that Troy Cox, chief executive officer, is scheduled to present at the 36th Annual J.

Foundation Medicine And Collaborators To Present New Data At The American Society Of Hematology (ASH) Annual Meeting That Supports Use Of FoundationOne®Heme To Advance Personalized Medicine In Blood Cancers

Foundation Medicine And Collaborators To Present New Data At The American Society Of Hematology (ASH) Annual Meeting That Supports Use Of FoundationOne®Heme To Advance Personalized Medicine In Blood Cancers

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that new data generated with FoundationOne ® Heme, its comprehensive genomic profiling (CGP) assay for hematologic malignancies and sarcomas, will be...

Foundation Medicine's Next-generation Sequencing Laboratory (Photo: Business Wire)

Foundation Medicine's Next-generation Sequencing Laboratory (Photo: Business Wire)

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the U.

Foundation Medicine Announces 2017 Third Quarter Results And Recent Highlights

Foundation Medicine Announces 2017 Third Quarter Results And Recent Highlights

Foundation Medicine, Inc. (NASDAQ: FMI) today reported financial and operating results for its third quarter ended September 30, 2017.

Foundation Medicine To Present Validation For FoundationOne CDx™, A Comprehensive Genomic Profiling Assay For Advancing Precision Cancer Care

Foundation Medicine To Present Validation For FoundationOne CDx™, A Comprehensive Genomic Profiling Assay For Advancing Precision Cancer Care

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the company will present validation data for FoundationOne CDx, its comprehensive genomic profiling assay, at the International Association for the Study of Lung...

Foundation Medicine Announces Timing For Third Quarter 2017 Financial Results And Conference Call

Foundation Medicine Announces Timing For Third Quarter 2017 Financial Results And Conference Call

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's third quarter ended September 30, 2017 will be released on Wednesday, November 1, 2017.

Foundation Medicine Appoints Tom Civik As Chief Commercial Officer

Foundation Medicine Appoints Tom Civik As Chief Commercial Officer

Foundation Medicine, Inc. (NASDAQ:FMI) today announced the appointment of Tom Civik to the role of chief commercial officer.

Foundation Medicine Receives Approval From The State Of New York For Its FoundationACT Liquid Biopsy Assay

Foundation Medicine Receives Approval From The State Of New York For Its FoundationACT Liquid Biopsy Assay

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that it received approval from the New York State (NYS) Clinical Laboratory Evaluation Program (CLEP) for its FoundationACT® blood-based circulating tumor DNA...

FOUNDATION MEDICINE 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors Of Deadline In Class Action Lawsuit Against Foundation Medicine, Inc. - (FMI)

FOUNDATION MEDICINE 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors Of Deadline In Class Action Lawsuit Against Foundation Medicine, Inc. - (FMI)

ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until September 26, 2017 to file lead plaintiff applications in a securities class action lawsuit against Foundation Medicine, Inc.

Glancy Prongay & Murray Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Foundation Medicine, Inc. (FMI)

Glancy Prongay & Murray Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Foundation Medicine, Inc. (FMI)

Glancy Prongay & Murray LLP ("GPM") reminds investors of the September 26, 2017 deadline in the class action lawsuit filed on behalf of investors who purchased Foundation Medicine, Inc.

Glancy Prongay & Murray LLP Commences Investigation On Behalf Of Foundation Medicine, Inc. Investors (FMI)

Glancy Prongay & Murray LLP Commences Investigation On Behalf Of Foundation Medicine, Inc. Investors (FMI)

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Foundation Medicine, Inc.

FOUNDATION MEDICINE SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Foundation Medicine, Inc. - (FMI)

FOUNDATION MEDICINE SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Foundation Medicine, Inc. - (FMI)

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 26, 2017 to file lead plaintiff applications in a securities class action lawsuit against Foundation Medicine, Inc.

Foundation Medicine To Present Validation Data For Its Assay Measuring Tumor Mutational Burden In Blood (bTMB), A New, Non-Invasive Predictor Of Response To Immunotherapy

Foundation Medicine To Present Validation Data For Its Assay Measuring Tumor Mutational Burden In Blood (bTMB), A New, Non-Invasive Predictor Of Response To Immunotherapy

Foundation Medicine, Inc. (NASDAQ:FMI) today announced presentations at the European Society for Medical Oncology (ESMO) Annual Meeting highlighting validation data for its novel assay to measure tumor mutational burden...

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Foundation Medicine, Inc. To Contact The Firm

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Foundation Medicine, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of...

Foundation Medicine To Present At The 2017 Wells Fargo Healthcare Conference

Foundation Medicine To Present At The 2017 Wells Fargo Healthcare Conference

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the 2017 Wells Fargo Healthcare Conference in Boston on Thursday, September 7, 2017, at 10:35 a.

Short Interest In Foundation Medicine Falls 10%

Short Interest In Foundation Medicine Falls 10%

The most recent short interest data has been released for the 08/15/2017 settlement date, which shows a 301,180 share decrease in total short interest for Foundation Medicine Inc , to 2,686,430, a decrease of 10.08% since 07/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

The Klein Law Firm Reminds Investors Of A Class Action Filed On Behalf Of Foundation Medicine, Inc. Shareholders And A Lead Plaintiff Deadline Of September 26, 2017

The Klein Law Firm Reminds Investors Of A Class Action Filed On Behalf Of Foundation Medicine, Inc. Shareholders And A Lead Plaintiff Deadline Of September 26, 2017

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Foundation Medicine, Inc.

The Klein Law Firm Announces A Class Action Filed On Behalf Of Foundation Medicine, Inc. Shareholders And A Lead Plaintiff Deadline Of September 26, 2017

The Klein Law Firm Announces A Class Action Filed On Behalf Of Foundation Medicine, Inc. Shareholders And A Lead Plaintiff Deadline Of September 26, 2017

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Foundation Medicine, Inc.

TheStreet Quant Rating: D (Sell)